A Study of GWP42006 in People With Focal Seizures - Part B

Summary

To investigate the potential antiepileptic effects of GWP42006 as add-on therapy in subjects with inadequately controlled focal seizures.

Timeline

Start

2016-03

Primary completion

2017-07

Completion

2017-09

Outcome

Missed primary endpoint

paper treatment ratio [% reduction] CBDV/placebo: 0.95 [4.6]; confidence interval: 0.78-1.17 [-16.7 to 21.9]; p=0.648 PMID 33998885 ↗

paper a treatment difference from placebo was not observed. PMID 33998885 ↗

Publications

• Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A; GWEP1330 Study Group. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidivarin	Small molecule	800 mg	—

Indications